Physician profile
Lawrence Flechner
NPI 1689815458
$22,109.81
in general payments reported to CMS, 2019-2025
70 companies · $2,862 in 2025
The $2,862 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,004 · 2020: $3,028 · 2021: $3,358 · 2022: $4,402 · 2023: $2,953 · 2024: $2,504 · 2025: $2,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,220 · Education: $97.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,220.39 |
| Education | $97.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,877.37 | 2019-2025 | |
| Sn Holdings, LLC | $2,309.69 | 2021-2023 | |
| Teleflex LLC | $1,570.09 | 2021-2025 | Urolift, Barrigel, Solesta |
| Dendreon Pharmaceuticals LLC | $1,515.15 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $1,343.06 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $1,135.78 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Abbvie INC. | $1,111.03 | 2019-2025 | |
| Pfizer INC. | $913.42 | 2019-2025 | |
| Neotract INC. | $846.14 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $777.75 | 2019-2025 | Yonsa |
| Sumitomo Pharma America, INC. | $757.30 | 2023-2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals Lp | $621.35 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $559.29 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Urogen Pharma, INC. | $380.01 | 2020-2025 | Jelmyto |
| Seagen INC. | $353.02 | 2020-2023 | Tukysa |
Show all 69 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379,273.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Flechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.